HRMY Harmony Biosciences Holdings, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Harmony Biosciences Holdings, Inc. (HRMY) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 24, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 14, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Harmony Biosciences Holdings, Inc. (HRMY) (SEC CIK 1802665), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Neuroscience-focused biopharma developing innovative treatments for rare neurological diseases emphasizing sleep/wake disorders, rare epilepsy, and neurobehavioral conditions
- • New products and expansions: Acquired orexin 2 receptor agonist BP1.15205 (preclinical), launched Phase 3 trials for next-gen pitolisant formulations (GR and HD), expanded rare epilepsy pipeline via Epygenix acquisition with EPX-100 and EPX-200
Risk Factors
- • Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026
- • Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks
Management Discussion & Analysis
- • Revenue $868.5M, up 21.5% YoY (+$153.7M) driven by 18.3% volume growth and 7.0% price increase, offset by 3.6% higher rebates
- • Gross margin 77.2% (cost of sales 22.8%) vs 78.1% (cost of sales 21.9%) in prior year, impacted by higher royalty tier
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New clinical trial risk for Pitolisant PWS Phase 3 TEMPO study initiated Q1 2024 after FDA alignment Oct 2023 and Orphan designation Feb 2024
- • Updated regulatory risk: FDA approved pediatric EDS label June 2024 but denied pediatric cataplexy sNDA; Type A meeting held Oct 2024 with resubmission Q3 2025
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Harmony Biosciences posted an investor presentation on Feb 24, 2026 to its IR website for use in analyst/investor meetings
- • Presentation is "furnished" not "filed" — not subject to Exchange Act Section 18 liability, limiting investor recourse
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings reported Feb 24, 2026 — see Exhibit 99.1 for detailed financials
- • Results cover quarter and year ended Dec 31, 2025
Annual Reports Archive10-K
AI-powered analysis of Harmony Biosciences Holdings, Inc. (HRMY) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Harmony Biosciences Holdings, Inc. (HRMY) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Harmony Biosciences Holdings, Inc. (HRMY) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $582.0M | $714.7M | $868.5M |
| Gross Profit | — | $460.8M | $557.9M | $670.1M |
| Operating Income | — | $192.0M | $190.8M | $208.5M |
| Net Income | — | $128.9M | $145.5M | $158.7M |
| Gross Margin | — | 79.2% | 78.1% | 77.2% |
| Op. Margin | — | 33.0% | 26.7% | 24.0% |
| Net Margin | — | 22.1% | 20.4% | 18.3% |
| Balance Sheet | ||||
| Total Assets | $673.9M | $811.4M | $999.2M | $1.3B |
| Equity | $402.8M | $467.0M | $659.2M | $870.2M |
| ROE | — | 27.6% | 22.1% | 18.2% |
Source: XBRL financial data from Harmony Biosciences Holdings, Inc. (HRMY) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 14, 2026 | — | — | — |
8-K | Apr 2, 2026 | — | — | — |
8-K | Feb 24, 2026 | — | Analysis | — |
10-K | Feb 24, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 25, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 29, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 30, 2024 | Mar 31, 2024 | — | |
10-K | Feb 22, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 31, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 1, 2023 | Jun 30, 2023 | — | |
10-Q | May 2, 2023 | Mar 31, 2023 | — | |
10-K | Feb 21, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 1, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 2, 2022 | Jun 30, 2022 | — | |
10-Q | May 3, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | May 11, 2021 | Mar 31, 2021 | — | |
10-K | Mar 25, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 12, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest HRMY SEC filings in 2026?
Harmony Biosciences Holdings, Inc. (HRMY) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 14, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did HRMY file its most recent 10-K annual report?
Harmony Biosciences Holdings, Inc. (HRMY) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view HRMY 10-Q quarterly reports?
Harmony Biosciences Holdings, Inc. (HRMY)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every HRMY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has HRMY filed recently?
Harmony Biosciences Holdings, Inc. (HRMY)'s most recent 8-K was filed on April 14, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find HRMY insider trading activity (Form 4)?
SignalX aggregates every HRMY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does HRMY file with the SEC?
Harmony Biosciences Holdings, Inc. (HRMY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HRMY filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Harmony Biosciences Holdings, Inc. (HRMY).
What is HRMY's SEC CIK number?
Harmony Biosciences Holdings, Inc. (HRMY)'s SEC CIK (Central Index Key) number is 1802665. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1802665 to look up all HRMY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find HRMY return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Harmony Biosciences Holdings, Inc. (HRMY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Harmony Biosciences Holdings, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 25+ filings.